Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | ACACA | Q13085 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478440 | 0.84 | CYP2D6 (0.52) | — | |
| SCHEMBL14871996 | 0.84 | CYP2D6 (0.52) | — | |
| SCHEMBL2777368 | 0.84 | CYP2D6 (0.52) | — | |
| SCHEMBL11503746 | 0.78 | SRC (0.47) | ALDH1A1 | |
| SCHEMBL2775701 | 0.76 | HDAC3 (0.43) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9041460 | 0.76 | LMNA (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5954418 | 0.75 | MMP2 (0.55) | SRD5A2TGM2PTGS1ALDH1A1HPGD | |
| SCHEMBL5954420 | 0.75 | MMP2 (0.55) | SRD5A2TGM2PTGS1ALDH1A1HPGD | |
| SCHEMBL8645113 | 0.74 | OPRK1 (0.44) | SMN1; SMN2 | |
| SCHEMBL10402082 | 0.74 | OPRK1 (0.44) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020198062-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | SRD5A2 2283/4885ACACB 789/4885ACACA 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.